Managing the Increasing Burden of Atrial Fibrillation through Integrated Care in Primary Care: A Cost-Effectiveness Analysis

Carline J van den Dries; Miriam P van der Meulen; Geert W J Frederix; Arno W Hoes; Karel G M Moons; Geert-Jan Geersing

doi:10.5334/ijic.5661

Managing the Increasing Burden of Atrial Fibrillation through Integrated Care in Primary Care: A Cost-Effectiveness Analysis

Int J Integr Care. 2023 May 3;23(2):9. doi: 10.5334/ijic.5661. eCollection 2023 Apr-Jun.

Authors

Carline J van den Dries^#¹, Miriam P van der Meulen^#¹, Geert W J Frederix¹, Arno W Hoes¹, Karel G M Moons¹, Geert-Jan Geersing¹

Affiliation

¹ Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht and Utrecht University, Str. 6.131, PO Box 85500, 3508 GA Utrecht, the Netherlands.

^# Contributed equally.

Abstract

Introduction: Integrated care for patients with atrial fibrillation (AF) in primary care reduced mortality compared to usual care. We assessed the cost-effectiveness of this approach.

Methods: Dutch primary care practices were randomised to provide integrated care for AF patients or usual care. A cost-effectiveness analysis was performed from a societal perspective with a 2-year time horizon to estimate incremental costs and Quality Adjusted Life Years (QALYs). A sensitivity analysis was performed, imputing missing questionnaires for a large group of usual care patients.

Results: 522 patients from 15 intervention practices were compared to 425 patients from 11 usual care practices. No effect on QALYs was seen, while mean costs indicated a cost reduction between €865 (95% percentile interval (PI) -€5730 to €3641) and €1343 (95% PI -€6534 to €3109) per patient per 2 years. The cost-effectiveness probability ranged between 36% and 54%. In the sensitivity analysis, this increased to 95%-99%.

Discussion: Results should be interpreted with caution due to missing information for a large proportion of usual care patients.

Conclusion: The higher costs from extra primary care consultations were likely outweighed by cost reductions for other resources, yet this study doesn't give sufficient clarity on the cost-effectiveness of integrated AF care.

Keywords: atrial fibrillation; cost-effectiveness; integrated care; multimorbidity; primary care.

Grants and funding

The ALL-IN trial is funded with an unrestricted grant from the Stichting Achmea Gezondheidszorg (SAG number Z646), the Hein Hogerzeil Stichting and Roche Diagnostics Nederland B.V. There are no restrictions to the execution of the study or the publication process by any of the subsiding parties of this study.